Anika Therapeutics, Inc.
NASDAQ:ANIKMedical - Devices
-$0.06 today
- Market cap
- $182.44M
- Beta
- 0.23
- P/E (TTM)
- -17.3
- EPS (TTM)
- -$0.82
Volume 0.12M
Average 0.11M
ANIK Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Anika Therapeutics, Inc.NASDAQ: ANIK
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $1.41M fell 11.6% year over year, ahead of the -27.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 6.8% from the prior quarter. Over 3 fiscal years it compounded at -26.6% a year.
Context
- Depreciation & amortization amounted to 5.1% of revenue in FY2025, down 1.7 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -11.6% holds above the trailing-twelve-month pace of -27.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 5.73M USD
- Year-over-year change
- -29.5%
- 4-year CAGR
- -20.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.73M | -29.5% |
| FY2024 | 2024-12-31 | 8.12M | -42.9% |
| FY2023 | 2023-12-31 | 14.22M | -1.9% |
| FY2022 | 2022-12-31 | 14.49M | +1.2% |
| FY2021 | 2021-12-31 | 14.32M | — |
Depreciation & Amortization vs competitors
How ANIK compares with its peers on the latest reported figures
- ANIK's LTM Mar 2026 depreciation & amortization of $5.54M is the 2nd largest of the 9 companies compared; the peer median is $2.4M.
- Its year-over-year change of -27.5% is the 8th highest of 9, against a peer median of +9.7%.
- Depreciation & amortization amounts to 4.8% of revenue for ANIK, versus a peer median of 9.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $429.44M | +48315.3% | -23.3% | 8364.7% | |
| LTM Mar 2026 | $5.54M | -27.5% | -26.6% | 4.8% | |
| LTM Mar 2026 | $4.68M | +4.5% | +24.0% | 14.5% | |
| LTM Mar 2026 | $4.56M | +11.6% | +9.7% | 7.9% | |
| LTM Mar 2026 | $3.11M | -8.6% | +4.7% | 9.0% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.69M | +7.8% | +29.0% | 91.1% |
| LTM Mar 2026 | $719K | +24.0% | -9.7% | 1.3% | |
| LTM Mar 2026 | $627K | -41.1% | -39.6% | 0.6% | |
| LTM Apr 2026 | $75K | +150.0% | — | — | |
| Peer median (excluding ANIK) | $2.4M | +9.7% | +4.7% | 9.0% | |
Competitors are the stored peer set for ANIK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 4.13M | (14.86M) | (82.67M) | (56.39M) | (10.88M) |
| Depreciation & Amortization | 14.32M | 14.49M | 14.22M | 8.12M | 5.73M |
| Deferred Income Tax | (1.77M) | (5.27M) | (6.33M) | 260K | (7K) |
| Stock-Based Compensation | 11.09M | 14.32M | 15.24M | 13.13M | 10.08M |
| Change in Working Capital | (14.72M) | (11.82M) | (12.12M) | (13.09M) | (823K) |
| Accounts Receivables | (6.22M) | (5.63M) | (1.31M) | 3.37M | 408K |
| Inventory | (6.62M) | (6.87M) | (11.4M) | (9.42M) | 30K |
| Accounts Payables | (1.1M) | 1.97M | (11K) | (2.51M) | 42K |
| Other Working Capital | (783K) | (1.28M) | 589K | (4.53M) | (1.3M) |
| Other Non-Cash Items | (4.66M) | 7.56M | 69.87M | 53.37M | 7.09M |
| Operating Cash Flow | 8.4M | 4.41M | (1.79M) | 5.4M | 11.19M |
| Capital Expenditures | (5.14M) | (7.49M) | (5.43M) | (7.73M) | (6.83M) |
| Acquisitions (Net) | (476K) | 0 | 0 | 0 | 8.99M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 2.5M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (600K) | (2.57M) |
| Investing Cash Flow | (3.12M) | (7.49M) | (5.43M) | (8.33M) | (401K) |
| Debt Repayment | (201K) | (284K) | 0 | 0 | 0 |
| Common Stock Issued | 1.13M | 681K | 0 | 0 | 500K |
| Common Stock Repurchased | 0 | 0 | (5M) | (10.91M) | (9.49M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.71M) | (5.25M) | (1.32M) | (1.82M) | (1.57M) |
| Financing Cash Flow | (6.78M) | (4.85M) | (6.32M) | (12.73M) | (10.55M) |
| Effect of Forex Changes | 69K | (130K) | 79K | (48K) | 86K |
| Net Change in Cash | (1.43M) | (8.06M) | (13.46M) | (15.71M) | 322K |
| Free Cash Flow | 3.25M | (3.08M) | (7.22M) | (2.33M) | 4.36M |
Anika Therapeutics, Inc.
NASDAQ:ANIK
Intrinsic Alpha fair value
Locked
Current Price
$13.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.